Product review · Updated September 30, 2026
Paula’s Choice 2% BHA Liquid: which pore result belongs to which page?
A pore-appearance claim has a study group and a market, while blackhead, barrier and glow claims have separate accounts.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
Paula’s Choice Skin Perfecting 2% BHA Liquid Exfoliant offers more than an ingredient percentage. Its US page makes claims about the appearance of pores, oil, blackheads and the skin barrier. Those claims become more useful when each is attached to its own footnote rather than treated as one overall result.
The UK record calls the product an Exfoliating Toner and supplies additional study summaries. This review keeps the two markets separate. It also distinguishes a change in how pores look from an acne outcome, without assuming that an advertised improvement answers every concern someone can see in a mirror.
In this article
A liquid identity with a second market name
The US product record identifies a liquid exfoliant and describes a lightweight toner. Its displayed full bottle is 4 fluid ounces. The UK page uses Skin Perfecting 2% BHA Exfoliating Toner and names 2% salicylic acid. Keeping the market beside the name matters when discussing its claims.
These records establish how the manufacturer presents the product. They do not establish that a bottle bought elsewhere carries the same declaration or evidence statement. A familiar name can connect two pages without making every footnote interchangeable. This review follows the US offer and uses the UK record as a clearly identified comparison of what the manufacturer discloses.
Visible pores are the named appearance outcome
Paula’s Choice advertises smaller-looking enlarged pores alongside oil control and clearer-looking skin. Those are manufacturer claims on the US page, not observations made for this review. The word appearance is useful: it identifies what someone is being told may look different, rather than promising that every visible opening has disappeared.
The AAD pore guidance describes oil and clogging as contexts that can make pores more noticeable, and also discusses lost firmness. That broader picture does not validate this toner’s results. It explains why the product’s particular endpoint deserves attention. The visible-pores guide offers a separate reading of the vocabulary used for pores and blackheads.
Thirty-two subjects, two different durations
The US summary attributes visible pore reduction and oil control to an independent clinical study involving 32 subjects after four weeks. The UK summary assigns those same named outcomes to 32 subjects after three weeks. Both market records are retained, including the UK footnote; the discrepancy is left unresolved.
A count of subjects does not explain recruitment, measurement, comparison conditions or the size of the reported change. We did not obtain the full study report. It would be misleading to choose the shorter period, average the periods, or describe the two website summaries as two confirmed independent experiments. The available evidence is the manufacturer’s account of a study, with a meaningful difference in its stated duration.
Blackheads and the barrier have their own footnotes
The UK summary links visible blackhead and whitehead reduction to 33 subjects after one week. It separately links line smoothing and brighter-looking skin to 29 subjects after three weeks. Its barrier statement mentions 29 subjects without supplying that same explicit period. The US barrier statement also names 29 subjects.
Those details should remain beside their respective outcomes. They do not enlarge the 32-subject pore group or prove that everyone experienced all the advertised changes. Someone interested in blackheads is reading a different account from someone interested in lines or the barrier. The salicylic-claims guide provides background for keeping ingredient claims and observed outcomes apart, without converting study periods into a personal schedule.
A complete UK list cannot fill an empty US panel
The examined US ingredient panel does not supply a complete declaration. The UK declaration does: it carries the identifier il402v1 and includes salicylic acid, green tea leaf extract and the rest of its listed base. That makes it useful evidence for the UK item, with its market kept visible.
We do not present that list as a verified US bottle formula. The distinction also limits any inference about an individual ingredient’s contribution to a finished-product outcome. A complete declaration tells us what is named, while the manufacturer’s study summary tells us what it claims to have observed. Neither record, by itself, supplies an ingredient-by-ingredient explanation of the reported pore result.
Faster glow language answers another question
The US page describes smooth, clear, glowing skin in as little as one week and refers broadly to clinical studies and consumer panels. A UK FAQ mentions smoother, clearer, glowing skin in as little as 48 hours while saying results can vary. These statements do not replace the market-specific pore footnotes.
Their broader wording is a reason to identify the claimed result before comparing time claims. Related documentation questions appear in the Effaclar cleanser review and Clinique gel review. Those are separate product readings; their evidence should not be used to fill gaps in Paula’s Choice testing or to declare a faster pore-clearing winner.
What the product record usefully establishes
The manufacturer records provide unusually specific participant counts for several appearance claims. Their value is in that specificity, including the unresolved three-versus-four-week difference. They do not provide the full methods needed to judge the pore result’s magnitude or its relevance to an individual reader.
FDA’s cosmetic-claims discussion distinguishes appearance claims from disease-treatment purposes and explains that cosmetic claims are not preapproved. This is a general boundary, not a product approval or legality audit. The format comparison can place a liquid beside other product forms. For this liquid, the most defensible conclusion stays with the particular market, endpoint and footnote actually supplied.
Sources behind this reading
- Paula’s Choice Skin Perfecting 2% BHA Liquid Exfoliant: US record ↗Official manufacturer product record; exact market and selected claim scope · Checked September 30, 2026
- Paula’s Choice Skin Perfecting 2% BHA Exfoliating Toner: UK record ↗Official manufacturer product record; exact market and selected claim scope · Checked September 30, 2026
- American Academy of Dermatology: making pores less noticeable ↗Medical society patient guidance · Checked September 30, 2026
- FDA: cosmetic claims and drug-purpose distinctions ↗Regulator explanation of labeling claims · Checked September 30, 2026